Cancer52 is delighted to announce the appointment of Chris Walden as our new CEO. Chris brings a wealth of experience from his work with both membership organisations and cancer charities.
He joins us from Blood Cancer UK, a Cancer52 charity member, where he was Deputy Director of Policy, Campaigns, and Engagement. Notably, he led the production of their recently launched Blood Cancer Action Plan. Prior to this, Chris served as Head of Public Affairs for Macmillan, provided freelance public affairs consultancy, and was a Senior Director at the Association of Colleges.
Chris succeeds Jane Lyons, whose leadership set a high standard. He is poised to build on these solid foundations by bringing fresh perspectives and continued dedication to Cancer52’s mission. Chris’s first day as the CEO of Cancer52 will be 21st October 2024.
“I have long appreciated the impact of Cancer52’s work and can’t wait to take on the CEO role and lead Cancer52 forward. Jane did a fantastic job of making Cancer52 the remarkable organisation it is today, and I’m excited to continue this growth. A family experience with rare and less common cancers adds a deeply personal commitment to my new role.”
Chris Walden
The Cancer52 Board has expressed strong support for Chris’s appointment. Chair of the
Board, Anne MacDowell, says “We are thrilled to welcome Chris Walden as our new CEO. Chris has a wealth of experience to lead Cancer52 to the next level. His exceptional influencing and membership engagement skills will be huge assets, and I look forward to working with him.”
Chris is already well known within the organisation, having previously served as a Trustee and Chair of the Cancer52 Policy and Public Affairs Steering Group (PPASG). Cancer52 looks forward to Chris’s leadership in advancing the cause of those affected by rare and less common cancers.
Please join us in congratulating Chris on his new role!
Comments